Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
Robert T NaismithBarry HendinSibyl WrayDeRen HuangFiorenza GaudenziQunming DongBjørn SperlingMonica MannBrian WerneburgPublished in: Multiple sclerosis journal - experimental, translational and clinical (2019)
Most patients who switched from non-pegylated interferon to peginterferon beta-1a did not experience new/worsening flu-like symptoms. Flu-like symptom duration per injection increased, but the cumulative duration significantly decreased. These data may inform flu-like symptom management guidance.
Keyphrases
- end stage renal disease
- dendritic cells
- ejection fraction
- newly diagnosed
- patient reported
- chronic kidney disease
- clinical trial
- study protocol
- prognostic factors
- recombinant human
- electronic health record
- randomized controlled trial
- immune response
- phase iii
- physical activity
- phase ii
- depressive symptoms
- patient reported outcomes